Key result
Specific circulating amino acid profiles are consistently linked to higher cardiometabolic risk.
Answers are grounded in this paper and cite their sources.
Specific plasma amino acid signatures, particularly elevated BCAAs, are consistently associated with increased cardiometabolic risk and may represent a novel therapeutic target.
PURPOSE OF REVIEW: To describe typical amino acid signatures for cardiometabolic risk and to discuss whether such signatures are a cause or merely a consequence of increased cardiometabolic risk. RECENT FINDINGS: Recent studies confirm the association between plasma amino acid levels and cardiometabolic risk across different populations and for multiple cardiometabolic traits, highlighting the value of plasma amino acid signatures as biomarkers. Preclinical studies targeting branched-chain amino acid (BCAA) catabolism show the potential of this novel strategy to improve cardiometabolic health. SUMMARY: Elevated plasma BCAA, aromatic amino acid (AAA), glutamate, low glycine, and a reduced glutamine-to-glutamate ratio are consistently linked to higher cardiometabolic risk, with impaired BCAA metabolism playing a bidirectional role in insulin resistance. Targeting BCAA catabolism may help lower BCAAs and their metabolites, offering a potential strategy to reduce cardiometabolic risk.
No takes yet. Share an insight, caveat, or question.
Marco Mensink (2025) conducted a review in Cardiometabolic risk. Plasma amino acid signatures (elevated BCAA, AAA, glutamate, low glycine) was evaluated. Elevated plasma branched-chain amino acids, aromatic amino acids, and glutamate, along with low glycine, are consistently linked to higher cardiometabolic risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: